Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 12/20 | 0.77 |
| ▸ | MTNR1A | P48039 | 6/20 | 0.76 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.45 |
| ▸ | CA1 | P00915 | 2/20 | 0.44 |
| ▸ | CA2 | P00918 | 2/20 | 0.44 |
| ▸ | ACHE | P22303 | 2/20 | 0.44 |
| ▸ | GHSR | Q92847 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5871334 | 0.87 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| SCHEMBL8650947 | 0.86 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| SCHEMBL8652117 | 0.85 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| SCHEMBL8650941 | 0.84 | MTNR1B (1.00) | MTNR1BMTNR1A | |
| SCHEMBL8652933 | 0.84 | MTNR1B (0.78) | MTNR1BMTNR1A | |
| SCHEMBL8648792 | 0.84 | MTNR1B (0.77) | MTNR1BMTNR1A | |
| SCHEMBL8653185 | 0.84 | MTNR1B (0.77) | MTNR1BMTNR1A | |
| SCHEMBL8653549 | 0.83 | MTNR1B (0.74) | MTNR1BMTNR1AGHSR | |
| SCHEMBL8653603 | 0.83 | MTNR1B (0.81) | MTNR1BMTNR1A | |
| SCHEMBL8652905 | 0.83 | MTNR1B (0.91) | MTNR1BMTNR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5780470-A | TREATING SLEEP DISORDERS AND DEPRESSION | BRISTOL-MYERS SQUIBB COMPANY (US) | 1998-07-14 | — | — | US | disclosed |
| EP-0745597-A2 | Novel melatonergic indanyl piperazines or homopiperazines | BRISTOL-MYERS SQUIBB COMPANY (US) | 1996-12-04 | — | — | EP | disclosed |